Type 2 diabetes: more than one type of diet can help people achieve remission

Aug 23, 2021

5 min

Dr Duane Mellor

Until recently, type 2 diabetes has mainly been managed by controlling risk factors – such as high blood pressure, cholesterol and blood sugar (glucose) levels – usually by prescribing drugs. But this approach doesn’t address the underlying causes of type 2 diabetes – such as problems with the hormone insulin no longer effectively controlling blood sugar. While taking drugs can help to manage blood sugar levels, it won’t help unpick the biological causes behind type 2 diabetes.



A growing body of research shows that losing weight, either through surgery or dieting, can help address some of the underlying causes of type 2 diabetes. It does this by helping the body control blood sugar levels. This is significant as controlling blood sugar by improving how insulin is made and works is key to bringing type 2 diabetes into remission.


Most of this body of research so far has looked at using meal-replacement shakes to help people with type 2 diabetes, which is why this approach may be prescribed by a doctor. But, more recently, researchers have begun investigating other diets – such as low-carbohydrate diets – in achieving remission. Although research in this area is still emerging, study results have so far shown a low-carbohydrate diet to be promising.


To better understand which diets are best at helping people achieve type 2 diabetes remission, our recent review looked at over 90 papers describing the effects of various diets on type 2 diabetes. We found that although the better quality research tended to focus on meal-replacement shakes used in clinical trials, other approaches (such as low-carbohydrate diets) were also shown to work well.


Join our readers who subscribe to free evidence-based news

Our review found that meal-replacement diets helped around one in three people successfully achieve remission, while low carbohydrate diets were able to help around one in five people achieve remission. People who lost weight using both of these diets were able to stay in remission for up to two years if they maintained their weight loss.


Low calorie and Mediterranean diets were also able to help people achieve remission – but at much lower rates. Only around 5% of people on low-calorie diets stayed in remission after one year, while only 15% of people on a Mediterranean diet stayed in remission after a year.


Defining remission

One of the big challenges we faced when writing our review was defining what “remission” is. Knowing how to define it was important so we could understand which diets worked best in helping people achieve remission.

The reason this was difficult is because the definition varies between different expert groups and research studies. Most define remission as a reduction of blood sugar levels below the range to diagnose diabetes – but some definitions state that this needs to be done without the use of drugs, while others do not. Other definitions say weight (especially fat around the midsection) must be lost to achieve remission.


Another challenge we faced when defining remission was that some reports suggest low-carbohydrate diets can normalise blood sugar levels even without weight loss. This happens because when we eat carbohydrates, they’re broken down into sugars which cause our blood sugar levels to rise. A low-carbohydrate diet means less blood sugar appears in the bloodstream, leading to improved blood sugar control.


For that reason, we initially defined remission using the definition each study used. Then, we compared the numbers of people whose blood sugar levels normalised without drugs for at least six months – which most consider to be true remission.


Mitigation v remission

While low-carbohydrate diets help people achieve remission, there’s concern that blood sugar levels could potentially rise again as soon as more carbohydrates are eaten. This is why we suggest in our review that rather than call this remission, it should perhaps be called “mitigation of diabetes”, as type 2 diabetes is still present – but the negative effects are being well managed. We think that remission can only be achieved if fat is lost from around the organs. This allows insulin to be made and used effectively again.


But because carbohydrates are also a major energy source in our diet, eating less of these often results in consuming fewer calories – which typically results in weight loss. So if someone is able to maintain a low-carbohydrate diet long term, they will not only reduce blood sugar levels and risk of complications for their diabetes, but may also achieve remission.


Regardless, the evidence that we looked at in our review made clear that there are many ways a person can significantly improve their blood sugar levels through diet – and that this can lead to remission in many cases. The key thing we found with each type of diet is that at least 10-15kg of body weight needed to be lost to achieve remission.


However, although weight loss seems to be the best predictor of success, it assumes fat loss from the pancreas and liver. It will be important for future studies to compare how these diets work for different ethnic groups, as type 2 diabetes can happen at lower body weights in different ethnic groups, who may have less weight to lose.


Not everyone may be able to achieve remission, but people who are younger (less than 50), male, have had type 2 diabetes for less than six years and lose more weight are more likely to be successful. This could be because these people are able to reverse the causes of their diabetes, recovering more of the pancreas’s ability to make insulin and the liver’s ability to use it. But this doesn’t mean others won’t be successful if they improve their diet and lifestyle, and lose weight.


Whether or not a person achieves remission, reducing blood sugar levels is important in managing the negative effects of type 2 diabetes and reducing risk of complications. But when it comes to choosing a diet, the most important thing is to pick one that suits you – one that you’re likely to stick to long term.



Connect with:
Dr Duane Mellor

Dr Duane Mellor

Visiting Academic

Dr Mellor is an award-winning dietitian, science communicator, medical educator and researcher.

Food ScienceDieteticsDiabetesObesityNutrition
Powered by

You might also like...

Check out some other posts from Aston University

2 min

Aston University economists say Prime Minister can reduce UK trade vulnerability with China visit

Greenland episode exposed UK’s lack of effective response to economic coercion from allies Research shows tariff retaliation would have cost the average UK household up to £324 per year Economists say China visit is “portfolio risk management” – diversification reduces vulnerability. The Prime Minister’s visit to China – the first by a British PM since 2018 – is an opportunity to reduce the UK’s vulnerability to economic coercion, according to new research from Aston University. A policy paper from Aston Business School’s Centre for Business Prosperity analyses the January 2026 Greenland tariff episode, when President Trump threatened and then withdrew tariffs on eight European countries. The researchers found that the UK had no good options: retaliation would have made Britain worse off, while absorbing the tariffs left Europe without credible deterrence. Director of the centre for business prosperity, Professor Jun Du, said: “The Greenland episode was a wake-up call. When your principal security ally threatens economic coercion, the old assumptions about who is safe and who is dangerous no longer hold. “The PM’s China visit should be framed as portfolio risk management – building diversified trading relationships that reduce the UK’s exposure to any single partner. Just as investors don’t put all their money in one stock, countries shouldn’t put all their trade into one basket. A UK with multiple strong partnerships is harder to pressure, whether the pressure comes from Washington or Beijing.” The research found that coordinated UK–EU tariff retaliation would have cost British households up to £324 per year – the worst outcome modelled. But the authors argue that Europe has untapped leverage elsewhere: the US runs a €148 billion annual services surplus with the EU, and mutual investment exceeds €5.3 trillion. Associate professor of economics and co-author, Dr Oleksandr Shepotylo, said: “Tariff retaliation fails because it hurts consumers and distorts the economy – the retaliator suffers similarly to the target. But Europe has cards it isn’t playing. Services, investment screening, and regulatory access are pressure points where Europe can respond effectively.” UK exports to China fell by 10.4% in the year to Q2 2025, with goods exports down 23.1% – the sharpest decline among major trading partners. The researchers argue that this closes off the UK’s largest alternative market at precisely the moment US reliability is in question. The paper identifies three priorities for UK policy: Recognise the permanent incentives behind US tariffs. US tariff revenue hit $264 billion in 2025. Trade negotiations alone cannot resolve revenue-driven policy. Build UK–EU coordination on non-tariff instruments. Services, investment, procurement, and regulation offer leverage that tariffs do not. Treat China engagement as portfolio risk management. Concentration in any single market creates vulnerability. Diversification is not about picking sides – it’s about resilience. Professor Du added: “The question for the Prime Minister is whether to use this breathing space to build resilience – or wait for the next Greenland.” To read the policy paper in full, click on this link:

2 min

Medication adherence: Why it matters and how we can improve it – public lecture by Professor Ian Maidment

Professor Ian Maidment is a professor in clinical pharmacy at Aston Pharmacy School His inaugural lecture will explain why patients struggle with taking medication and present possible solutions to the problem Professor Maidment is a former practising pharmacist and an expert in medication optimisation and management in mental health and dementia. Professor Ian Maidment, professor in clinical pharmacy at Aston Pharmacy School, will give a public lecture about his life’s work on 5 February 2025. In his inaugural lecture, Professor Maidment will reflect on his journey from a childhood in Kent to becoming a leading researcher in clinical pharmacy. After more than two decades working in the NHS, in community pharmacy, mental health, dementia care, and leadership roles, he joined Aston University in 2012. His research focuses on the real-world challenges of medication optimisation for patients, carers, and healthcare professionals. The title of Professor Maidment’s lecture is ‘Medication adherence: Why it matters and how we can improve it’. Every year, the UK spends nearly £21 billion on medicines. Yet up to half of people with long-term conditions do not take their medication as prescribed—a problem known as non-adherence. This has profound clinical consequences and significant financial implications for the NHS. Professor Maidment will draw on his experience to explore how factors such as medication burden and side-effects influence adherence, the challenges posed by conditions such as dementia and severe mental illness, the role of pharmacy in supporting adherence and why tackling non-adherence requires a system-wide approach. He will also offer practical solutions to one of healthcare’s most persistent problems. Professor Maidment said: “We need to understand why patients struggle to take their medication and then develop and test solutions that work well.” The lecture on Thursday 5 February 2026 will take place at Aston Business School. In-person tickets are available from Eventbrite. The public lecture will begin at 18:00 GMT with refreshments served from 17:30 GMT. It is free of charge and will be followed by a drinks reception. The lecture will also be streamed online.

3 min

New research partnership to develop biodegradable gloves from food waste for healthcare sector

Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by the NHS each year. They create large volumes of clinical waste which has both an environmental and economic cost. The Knowledge Transfer Partnership (KTP) project will develop a more sustainable alternative made from polymers derived from food waste such as orange peel, able to degrade naturally. The gloves will initially be for use during low-risk tasks such as ultrasound scans, rather than in more critical situations such as operating theatres. The gloves would be designed to not only reduce clinical waste and costs in the NHS, but also carbon emissions, helping the NHS reach its goal to be the world’s first net-zero health service. With most personal protective equipment (PPE) currently sourced from Chinese manufacturers, the goal is to develop a biodegradable glove that can be manufactured using a UK supply chain. The challenging project draws on Aston University’s expertise in sustainable polymer chemistry, centred at Aston Institute for Membrane Excellence (AIME). Aston University has one of the largest research groups of polymer chemists in the UK. The project will be led at the University by Professor Paul Topham, director of AIME, and Dr James Wilson, AIME associate member. The research team have chosen to focus on polymers from food waste in order to ensure that the final product can be manufactured sustainably. Most polymers are currently made from petroleum. Polymers made from food waste, ranging from fruit waste to corn or dairy products, have the potential for antioxidant and antibacterial properties if designed appropriately. The team will manipulate the polymer molecules so that they include the right monomers (the smaller units which make up the molecules) in the right location to achieve the properties they require. Critical to the success of the project will be PFE Medical’s commercial and clinical experience of taking new innovations into medical use. It will be the third KTP between Aston University and PFE, following on from successful projects to develop an automated endoscope cleaner, now in use across University Hospitals Birmingham NHS Foundation Trust (UHB). Professor Topham said: “At Aston University, we have a long history of working with industry, of translating fundamental research into solutions for real world problems. This project with PFE Medical provides us with that route, to take our science and engineering and make a difference to peoples’ lives. That’s exactly where, as researchers, we want to be.” Rob Hartley, CEO of PFE Medical, said: “Our previous KTP with Aston University was a phenomenal success, thanks to the brilliant team we had on board. I’m just as excited by this project, which is looking to solve an equally long-standing problem. If we can achieve our goal, then the implications are huge, going far beyond the NHS to all the other situations where people are wearing disposable gloves.” KTPs, funded by Innovate UK, are collaborations between a business, a university and a highly qualified research associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is a sector-leading KTP provider, ranked first for project quality, and joint first for the volume of active projects. For further details about this KTP, visit the webpage: www.aston.ac.uk/business/collaborate-with-us/knowledge-transfer-partnership/at-work/pfe-medical.

View all posts